TAK-071   Click here for help

GtoPdb Ligand ID: 12302

Compound class: Synthetic organic
Comment: TAK-071 is a muscarinic M1 receptor positive allosteric modulator [1-2]. It has been shown to improve cognitive function in in vivo models.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 67.07
Molecular weight 421.18
XLogP 3.07
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O[C@H]1CCOC[C@@H]1N1Cc2c(C1=O)cc(c(c2F)C)Cc1ccc(cc1)n1cccn1
Isomeric SMILES Cc1c(c2c(cc1Cc1ccc(cc1)n1cccn1)C(=O)N(C2)[C@H]1COCC[C@@H]1O)F
InChI InChI=1S/C24H24FN3O3/c1-15-17(11-16-3-5-18(6-4-16)28-9-2-8-26-28)12-19-20(23(15)25)13-27(24(19)30)21-14-31-10-7-22(21)29/h2-6,8-9,12,21-22,29H,7,10-11,13-14H2,1H3/t21-,22-/m0/s1
InChI Key WFSARWQASFQZMG-VXKWHMMOSA-N
No information available.
Summary of Clinical Use Click here for help
TAK-071 has progressed to clinical trial to evaluate its efficacy to improve cognition in patients with Parkinson's and Alzheimer's diseases. Safety and pharmacokinetics in healthy subjects has been reported [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02769065 Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants Phase 1 Interventional Takeda
NCT04334317 A Study of TAK-071 in People With Parkinson Disease Phase 2 Interventional Takeda